Efficacy of Selinexor in Relapsed/Refractory Multiple Myeloma (RRMM) Patients with del17p and Other High-Risk Abnormalities (A Retrospective Single-Center Study)

Efficacy of Selinexor in Relapsed/Refractory Multiple Myeloma (RRMM) Patients with del17p and Other High-Risk Abnormalities (A Retrospective Single-Center Study)

Selinexor (Seli) is a first-in-class, oral selective inhibitor of the nuclear export protein, exportin-1 (XPO1). Seli exhibits its antitumor effect through the blockage of XPO1, which increases nuclear retention of tumor suppressor proteins (TSPs), including p53, thereby limiting the translation of...

Full description

Bibliographic Details
Main Authors: Hamid Ehsan, Myra Robinson, Peter M. Voorhees, Kristen Cassetta, Shanice Borden, Shebli Atrash, Manisha Bhutani, Cindy Varga, Mauricio Pineda-Roman, Reed Friend, Barry A. Paul
Format: Article
Language:English
Published: MDPI AG 2024-03-01
Series:Life
Subjects:
Selinexor
RRMM
high-risk multiple myeloma
Online Access:https://www.mdpi.com/2075-1729/14/3/384

Internet

https://www.mdpi.com/2075-1729/14/3/384

Similar Items